Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 660,736 |
|
|||||
| News | - | ||||||
| Day High | 1.08 | Low High |
|||||
| Day Low | 1.02 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Karyopharm Therapeutics Inc | KPTI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.02 | 1.89% | 1.08 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.05 | 1.02 | 1.08 | 1.05 | 1.06 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,965 | 660,736 | $ 1.05 | $ 691,603 | - | 0.6174 - 3.865 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:55:13 | 6 | $ 1.08 | USD |
Karyopharm Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 120.82M | 115.07M | - | 146.03M | -143.1M | -1.24 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Karyopharm Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KPTI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.26 | 1.305 | 1.02 | 1.11 | 1,129,754 | -0.18 | -14.29% |
| 1 Month | 1.51 | 1.65 | 1.02 | 1.27 | 1,165,435 | -0.43 | -28.48% |
| 3 Months | 0.91 | 1.95 | 0.8601 | 1.38 | 1,831,730 | 0.17 | 18.68% |
| 6 Months | 0.83 | 1.95 | 0.6174 | 1.13 | 1,483,434 | 0.25 | 30.12% |
| 1 Year | 3.77 | 3.865 | 0.6174 | 1.61 | 1,934,916 | -2.69 | -71.35% |
| 3 Years | 9.38 | 14.73 | 0.6174 | 4.85 | 2,176,579 | -8.30 | -88.49% |
| 5 Years | 4.80 | 29.61 | 0.6174 | 8.31 | 2,023,588 | -3.72 | -77.50% |
Karyopharm Therapeutics Description
| Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's lead compound, XPOVIO(R) (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade(R) (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. |
